This page shows the latest Atopic dermatitis news and features for those working in and with pharma, biotech and healthcare.
Sanofi attributed Dupixent’s growth in 2020 to continued demand in atopic dermatitis among adult and adolescent patients, as well as ‘rapid adoption’ of the drug in children.
The mAb recently met both primary endpoints in a phase 2a study in moderate-to-severe atopic dermatitis patients whose disease is inadequately controlled by topical corticosteroids.
PDE 4 inhibitors are already used to treat inflammatory diseases in the lungs and skin, such as Amgen’s Otezla (apremilast) for psoriasis and Pfizer’s Eucrisa (crisaborole) for atopic dermatitis.
It’s not the first time that serlopitant has been undermined by a high placebo response rate in trials, however, as the drug previously missed the mark in atopic dermatitis – much
set to begin in mid-2020 in adults and paediatrics with atopic dermatitis. ... Our team and advisors are committed to providing new treatment options, particularly for paediatrics with atopic dermatitis, for which few treatment options exist, and we look
Set for regulatory filings later this year. Incyte now has a pair of positive phase 3 trials for its topical formulation of JAK1/2 inhibitor ruxolitinib in atopic dermatitis or eczema, ... The trials recruited patients with mild-to-moderate atopic
More from news
Approximately 10 fully matching, plus 77 partially matching documents found.
pneumococcal vaccine due to be filed next year that would extend its $3.4bn Prevnar franchise, a Clostridium difficile vaccine in phase 3 and JAK inhibitors for atopic dermatitis and alopecia.
We needed to pique delegates’ interest and show them a new approach to treating atopic dermatitis. ... But, how? Before diving head-first into the idea, we enlisted the help of key stakeholders within atopic dermatitis.
The video played while the lift whisked its passengers into the congress, creating a six-minute video ‘experience’ which challenged dermatologists to change the way they treated atopic dermatitis. ... In order to target their message, the creative
It also unveiled mid-stage data on its JAK1 inhibitor upadacitinib in atopic dermatitis, adding another clinical win to earlier successes in rheumatoid arthritis. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis,
Innovation investment. Leo has the big beasts of psoriasis and atopic dermatitis firmly in its sights and is forging ahead on the quest to tackle unmet needs in dermatology. ... Bridging the gap. Leo is tracking increases in atopic dermatitis across
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
atopic dermatitis in the US.
Concerning his appointment, Grey said: “I am delighted to join Ziarco's board, as the company has a strong leadership team and promising lead compounds for the treatment of atopic dermatitis
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
Atopic dermatitis (AD) or eczema is a chronic inflammatory skin disease, which, although not as debilitating as other chronic conditions, can have a significant psychological impact on patients, or parents caring
Living with Atopic Dermatitis (AD) is a report based on a new study conducted amongst adult sufferers and parents of child sufferers. ... An attitudinal segmentation is included to help identify the unique groups of patients Atopic Dermatitis.
Living with Atopic Dermatitis (AD) is a study conducted amongst 100 adults and 50 caregivers in the US.
Atopic Dermatitis — Going Beyond the Pill.
More from PMHub
Approximately 4 fully matching, plus 1 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...